Le Lézard
Classified in: Health
Subject: FDA

Tirosint®-SOL Now Available to Treat Hypothyroidism in the U.S.

PARSIPPANY, N.J., Feb. 27, 2019 /PRNewswire/ -- IBSA Pharma Inc. announced that its Tirosint-SOL (levothyroxine sodium) oral solution is now available in the US market for the treatment of hypothyroidism and pituitary thyrotropin suppression.

Tirosint-SOL is the first and only liquid levothyroxine formulation approved by the FDA and is indicated for patients of all ages.  Levothyroxine is a hormone that is normally produced by the thyroid gland. It is used to treat patients who suffer from hypothyroidism or inadequate levels of thyroid stimulating hormone (TSH).

Tirosint-SOL is the latest product to be launched in the US by the IBSA Pharma Inc., a fully-owned subsidiary of IBSA Institute Biochemique SA. Tirosint-SOL's unique liquid formulation is made without excipients such as dyes, wheat starch (gluten), lactose, alcohol, sugar and others that may contribute to tolerability and absorption issues. It is packaged in monodose ampules in 12 different dosage strengths, including a 13 mcg/mL dose. Tirosint-SOL may be administered either directly into the mouth or diluted in a glass of water.

"Tirosint-SOL  is the only FDA approved oral liquid levothyroxine therapy. It will be available through participating mail order  and retail pharmacies starting March 1st, " stated Aldo Donati, CEO of IBSA Pharma. Tirosint-SOL has been studied extensively in Europe and the value of its unique formulation demonstrated by several clinical studies that have been published in scientific journals.  

"Tirosint-SOL represents an evolution in hypothyroidism treatment. While levothyroxine therapy has been available for decades, this is the first FDA-approved liquid levothyroxine formulation," said Dr. Murray Ducharme, Professeur Associé, Faculté de Pharmacie at the University of Montreal.  "This easy-to-swallow option will provide a useful new option for many patients who may benefit from a liquid rather than an oral solid version of this proven therapy."

IBSA offers several programs to provide patients who need Tirosint-SOL, with cost-effective access to Tirosint-SOL. For eligible patients with commercial insurance, the Tirosint-SOL Copay Savings Card may reduce the cost of Tirosint-SOL to as little as $15 per month of therapy. For patients without insurance or with high copays or deductibles, the Tirosint Direct Program is available through participating mail order pharmacies and offers the lowest cash price available. Additional information can be found at www.tirosintsol.com. IBSA also offers a Patient assistance Program (PAP) for qualifying indigent patients. Additional information can be found at http://www.ibsapap.com/.

IBSA Pharma is part of IBSA Group, which is headquartered in Lugano, Switzerland. The company is a world leader in the treatment of thyroid disease and has a diversified product portfolio of prescription drugs. With products on five continents and in over 80 countries, IBSA manufactures 14 million vials of hormones, 300 million soft gel capsules and 60 million packages of finished products every year. IBSA has a commitment to scientific research and improving the health of patients.

Important Safety Information



Warnings and Precautions   

Limitations of Use

Adverse Reactions 
Adverse reactions associated with TIROSINT-SOL are primarily those of hyperthyroidism due to therapeutic overdosage including: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash.

For more information, visit www.ibsagroup.com/media.

*For Full Prescribing Information, visit www.TirosintSOL.com


IBSA Institut Biochimique SA, Lugano, Switzerland (PRNewsfoto/IBSA Pharma, Inc.)


These press releases may also interest you

at 10:20
The "Global Digital Biomarkers Market: Focus on Key Trends, Growth Potential, Competitive Landscape, Components, End Users, Application (Sleep and Movement, Neuro, Respiratory and Cardiological Disorders) and Region - Analysis and Forecast,...

at 10:13
The Antibacterial Resistance Leadership Group (ARLG), a unique research network for which the Duke Clinical Research Institute (DCRI) acts as a coordinating center, received a federal award worth up to $102.5 million over seven years that will...

at 10:05
PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Human Care Systems as one of the most innovative companies of 2019. Human Care Systems, creator of...

at 10:05
PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Marketing Operations at Health & Wellness Partners, LLC (HWP) one of the most innovative Divisions of...

at 10:05
Sienna Senior Living Inc. ("Sienna" or the "Company") today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of December 2019, representing $0.936 per Common Share on an annualized basis. The...

at 10:00
TopConsumerReviews.com recently awarded their highest five-star rating to AuraGlow, an industry-leading product among Teeth Whiteners. It's been proven that a bright, white smile can make a huge difference in a first impression. For people looking to...

News published on 27 february 2019 at 08:03 and distributed by: